You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GM-CSF - human granulocyte macrophage colony-stimulating factor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

IVF, PCOS, IVM Trial in Ho Chi Minh City (GM-CSF group, Control group)

Recruiting
  • IVF
  • +2 more
  • GM-CSF group
  • Control group
  • Ho Chi Minh City, Vietnam
    My Duc Hospital
Jul 12, 2021

Neuroblastoma Trial (Naxitamab)

Not yet recruiting
  • Neuroblastoma
  • (no location specified)
Sep 18, 2023

Neuroblastoma Trial in New York (Hu3F8 With GM-CSF)

Active, not recruiting
  • Neuroblastoma
  • Hu3F8 With GM-CSF
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 2, 2022

Renal Cancer Trial in Boston (Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF))

Active, not recruiting
Has Results
  • Renal Cancer
  • Dendritic Cell Tumor Fusion Vaccine
  • Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Jan 2, 2023

Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)

Recruiting
  • Recurrent Osteosarcoma
  • humanized anti-GD2 antibody
  • GM-CSF
  • Los Angeles, California
  • +2 more
Dec 22, 2022

Breast Cancer Trial in Boston (Autologous, Lethally Irradiated Breast Cancer Cells)

Completed
Has Results
  • Breast Cancer
  • Autologous, Lethally Irradiated Breast Cancer Cells
  • Boston, Massachusetts
  • +1 more
Mar 30, 2022

Lymphoma, Non-Hodgkin, HIV Trial in Los Angeles (Bleomycin sulfate, Vincristine sulfate, Doxorubicin HCl)

Completed
  • Lymphoma, Non-Hodgkin
  • HIV Infections
  • Bleomycin sulfate
  • +8 more
  • Los Angeles, California
    USC CRS
Oct 26, 2021

Thymoma Trial in Shanghai (Radiotherapy Combined with GM-CSF)

Recruiting
  • Thymoma
  • Radiotherapy Combined with GM-CSF
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 2, 2022

Down Syndrome Trial in Aurora (Sargramostim for Injection, Saline Placebo)

Not yet recruiting
  • Down Syndrome
  • Sargramostim for Injection
  • Saline Placebo
  • Aurora, Colorado
    University of Colorado Anschutz Medical Campus
Jul 28, 2022

Granulocyte Colony-stimulating Factor, Stem Cell Mobilization Trial (PEG-rhG-CSF)

Not yet recruiting
  • Granulocyte Colony-stimulating Factor
  • Stem Cell Mobilization
  • (no location specified)
Jun 13, 2022

Sarcoma, Kaposi, HIV Trial in New York (Interferon alfa-2b, Zidovudine, Sargramostim)

Completed
  • Sarcoma, Kaposi
  • HIV Infections
  • Interferon alfa-2b
  • +2 more
  • New York, New York
    Mem Sloan - Kettering Cancer Ctr
Oct 26, 2021

Early-stage Breast Cancer Trial in Ottawa (Granulocyte Colony-Stimulating Factor (G-CSF), Omission of Granulocyte

Not yet recruiting
  • Early-stage Breast Cancer
  • Granulocyte Colony-Stimulating Factor (G-CSF)
  • Omission of Granulocyte Colony-Stimulating Factor (G-CSF)
  • Ottawa, Ontario, Canada
    The Ottawa Hospital Cancer Centre
Feb 22, 2023

Primary Ovarian Insufficiency, Premature Ovarian Failure Trial in Toronto (Neupogen)

Recruiting
  • Primary Ovarian Insufficiency
  • Premature Ovarian Failure
  • Toronto, Ontario, Canada
    Trio Fertility
Oct 31, 2023

Alcoholic Hepatitis Trial in Chandigarh (Standard Medical Therapy, G-CSF, G-CSF and NAC)

Completed
  • Alcoholic Hepatitis
  • Standard Medical Therapy
  • +2 more
  • Chandigarh, India
    Dept of Hepatology, PGIMER
Apr 29, 2023

Neuroblastoma Recurrent Trial in Hong Kong (Natural killer cell, Dinutuximab beta, Interleukin-2)

Recruiting
  • Neuroblastoma Recurrent
  • Natural killer cell
  • +4 more
  • Hong Kong, Hong Kong
    Hong Kong Children's Hospital
Feb 22, 2023

Hepatitis B, Chronic Trial in Beijing (Granulocyte Macrophage-colony Stimulating Factor, Entecavir)

Terminated
  • Hepatitis B, Chronic
  • Granulocyte Macrophage-colony Stimulating Factor
  • Entecavir
  • Beijing, Beijing, China
    302 Military Hospital
Mar 9, 2022

Alzheimer Trial in Aurora (Sargramostim, Saline - comparator)

Recruiting
  • Alzheimer Disease
  • Aurora, Colorado
    University of Colorado Anschutz Medical Campus
Jul 19, 2022

Pediatric Cancer, Neutropenia, Lenograstim Trial in Taoyuan (G-CSF administration (bolus injection versus intravenous infusion))

Recruiting
  • Pediatric Cancer
  • +4 more
  • G-CSF administration (bolus injection versus intravenous infusion)
  • Taoyuan, ROC, Taiwan
    Chang Gung Children Hospital
Nov 21, 2023

HIV, Cytopenias Trial in Buffalo (Zidovudine, Sargramostim)

Completed
  • HIV Infections
  • Cytopenias
  • Buffalo, New York
    SUNY / Erie County Med Ctr at Buffalo
Oct 27, 2021

Peripheral Artery Disease (PAD) Trial in Atlanta (GM-CSF, Placebo)

Recruiting
  • Peripheral Artery Disease (PAD)
  • Atlanta, Georgia
    Emory University Hospital
Oct 8, 2021

Neuroblastoma Trial in Worldwide (GM-CSF + Naxitamab)

Recruiting
  • Neuroblastoma
  • GM-CSF + Naxitamab
  • Gainesville, Florida
  • +22 more
Aug 29, 2022

Ependymoma, Recurrent Childhood, Ependymoma Trial in Denver, Orlando (Granulocyte Macrophage Colony Stimulation Factor)

Active, not recruiting
  • Ependymoma, Recurrent Childhood
  • Ependymoma
  • Granulocyte Macrophage Colony Stimulation Factor
  • Denver, Colorado
  • +1 more
Feb 8, 2022